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Abstract
Background: Epstein-Barr virus (EBV) infects resting B-lymphocytes and transforms them into
immortal proliferating lymphoblastoid cell lines (LCLs) in vitro. The transformed immunoblasts may
grow up as immunoblastic lymphomas in immuno-suppressed hosts.
Results: In order to identify cellular protein targets that may be involved in Epstein-Barr virus
mediated B-cell transformation, human LCL cDNA library was screened with one of the
transformation associated nuclear antigens, EBNA-3 (also called EBNA-3A), using the yeast two-
hybrid system. A clone encoding a fragment of a novel human protein was isolated (clone 538). The
interaction was confirmed using in vitro binding assays. A full-length cDNA clone (F538) was
isolated. Sequence alignment with known proteins and 3D structure predictions suggest that F538
is a novel human uridine kinase/uracil phosphoribosyltransferase. The GFP-F538 fluorescent fusion
protein showed a preferentially cytoplasmic distribution but translocated to the nucleus upon co-
expression of EBNA-3. A naturally occurring splice variant of F538, that lacks the C-terminal uracil
phosphoribosyltransferase part but maintain uridine kinase domain, did not translocate to the
nucleus in the presence of EBNA3. Antibody that was raised against the bacterially produced GST-
538 protein showed cytoplasmic staining in EBV negative Burkitt lymphomas but gave a
predominantly nuclear staining in EBV positive LCL-s and stable transfected cells expressing EBNA-
3.
Conclusion: We suggest that EBNA-3 by direct protein-potein interaction induces the nuclear
accumulation of a novel enzyme, that is part of the ribonucleotide salvage pathway. Increased
intranuclear levels of UK/UPRT may contribute to the metabolic build-up that is needed for blast
transformation and rapid proliferation.
Background
EBV is a gamma-herpes virus that is present in nearly all
humans in form of lifelong infection. EBV infection in ad-
olescence causes infectious mononucleosis. The virus as-
sociates with several human malignancies, particularly,
with Burkitt lymphoma (BL), nasopharyngeal carcinoma
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(NPC) and post transplant lymphoproliferative disease
[1].
In vitro EBV transforms B-cells into lymphoblastoid cell
lines (LCLs) that express 9 virally encoded proteins – the
nuclear proteins EBNA 1–6 and the membrane proteins
LMP1, 2A and 2B. Six of them – EBNA-1, -2, -3, -5 and -6
and LMP-1 are required for immortalisation of B-cells [1].
EBNA-3 (also called EBNA-3A) is a member of the EBNA-
3-protein family, designated as EBNA-3, 4 and 6, or in the
alternative nomenclature, EBNA-3A, B and C. These three
proteins bear a major responsibility for the induction of
the immune rejection response that makes mononucleo-
sis a self-limiting disease. All three proteins can bind to
the DNA binding protein RBP-Jk [2–8].
The role of the EBNA-3 family in the viral strategy is not
well understood [9,10]. We have previously identified two
cellular proteins that can bind to EBNA-3 in yeast two-hy-
brid system. The ε -subunit of the TCP1 chaperonin com-
plex may assist the initial folding of the nascent EBNA-3
[11]. The Xap-2 protein is a minor subunit of the aryl hy-
drocarbon receptor complex [12]. It is also a cellular target
for the Hepatitis B virus encoded X antigen. HBX is be-
lieved to be involved in HBV associated carcinogenesis
[13].
In this paper we have identified yet another human pro-
tein, designated F538, through its binding to EBNA-3. We
have found that it is homologous to human and mouse
uridine kinases, human uridine-cytidine kinase, and to
uracil phosphoribosyltransferases of Toxoplasma gondii, C.
elegans and Cryptosporidium parvum .
Results
RBP-Jk is one of the known interacting partners of EBNA-
3. It binds to the N-terminal part of EBNA-3. In order to
find additional targets of this large viral protein we used
an N-terminus truncated EBNA-3 cDNA clone (encoding
amino acids 127–945) for screening of a human lym-
phoblast cDNA library. We identified an interactive clone
(designated clone 538) that could grow on His, Leu and
Trp deficient medium and expressed β -galactosidase from
an interaction dependent reporter locus. Plasmid rescue
from the yeast to E. coli produced a clone with a ~800 bp
long insert at its XhoI site.
Retransformation of clone 538 DNA together with the
EBNA-3 construct into the yeast tester strain (SFY526)
confirmed the interaction. Plasmids containing EBNA-1,
∆ EBNA-4, EBNA-5, EBNA-6 and the empty pGBT9/BR
vector were also retransformed together with the clone
538 DNA as negative controls. None of them showed any
significant interaction in β -galactosidase test (Table 1).
The strongly interacting p53/SV40LT protein pair was
used as positive control.
XhoI cleaved insert of clone 538 was used as a probe on
Northern blots. The 2,4 kb transcript was detected ubiqui-
tously in all tissues with highest level expression in skele-
tal muscle, heart and kidney (Figure 1). We have detected
the same transcript in Burkitt lymphoma (BL) lines DG75,
DG75-EBNA-3, DG75-EBNA-5 and freshly established
LCL (data not shown).
Sequencing of the insert showed that clone 538 was iden-
tical to a part of a putative human gene with GenBank ac-
cession number of NM_017859.1, encoding the
hypothetical gene product FLJ20517 (accession number
NP_060329). The gene is consisted of fifteen exons that
are distributed on a 19580 nucleotide long region on
chromosome 20 (1325898–1306319).
To obtain the full-length cDNA (F538) we used a human
heart cDNA library for PCR-amplification. The full-length
cDNA was sequenced and cloned into green fluorescence
protein fusion vector pEGFP-C1 (GFP) and AD vectors.
The cDNA clone contained 1630 bp, encoding a 538 aa
long protein. The first 10 amino acids were omitted from
the cloning strategy because no selective primers could be
designed for this region.
We have also identified an alternatively spliced variant of
this gene (F538∆ C) where exon 12 was spliced to the mid-
dle of exon 11. This splice created a frameshift that led to
a stop-codon. The encoded protein product is truncated
from residue 386 with 10 extra amino acids prior to the
stop-codon (Figure 2). The alternatively spliced variant
was also recovered as EST from GenBank as mRNA ex-
pressed in different normal tissues such as optic nerve
(BM702108), retina (BM693202) and testis (AA382318).
Table 1: Specific activity in β -galactosidase units of 538 co-trans-
formants in yeast strain SFY526
Target DNA in BD vector β GU *
EBNA-1 0,6
EBNA-3 6,7
∆ EBNA-4 0,8
EBNA-5 0,8
EBNA-6 0,9
BD 0,6
* – Large T-p53 activity is 72,8 (30% of standard deviation after 4 
independent experiments)BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/23
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The exon structure of the gene and the location of PCR
primers are shown on Figure 3.
To analyse the protein-protein interaction in vitro, the in-
sert from yeast 538 clone (the coding region correspond-
ing to amino acids 216–473) was cloned into glutathione-
S-transferase bacterial expression vector (GST-2TK). Upon
induction, a 56 kD fusion protein was detected on silver
or Coomassie blue stained SDS acryl amide gels.
This and several other control GST proteins were used to
precipitate interacting proteins from lysates of CV-1 cells
that were infected with recombinant vaccinia virus ex-
pressing full length EBNA-3. GST-538, but not GST or
GST-EBNA-5 could precipitated EBNA-3 (Figure 4). GST-
Full436 containing the Xap-2 gene was used as positive in-
teraction control [12]. Lysates of cells, infected with re-
combinant vaccinia virus that expressed EBNA-2 were
included as non-specific precipitation controls.
To study the subcellular localization of the protein, GFP-
F538 and GFP-F538∆ C constructs were transfected into
CV1 cells. Protein expression was already detectable after
4–6 hours by direct fluorescence. At this time the protein
was homogeneously distributed in the cytoplasm. 24
hours after the transfection the protein started to form
granular precipitates of varying size that were restricted to
the cytoplasm. After 48 hours the protein formed large cy-
toplasmic inclusion bodies as the result of overexpression
(Figure 5).
EBNA-3 is a nuclear protein. In order to test if EBNA-3 has
any effect on the subcellular distribution of F538, CV-1
cells that were transfected with GFP-F538 or GFP-F538∆ C,
were superinfected with recombinant vaccinia virus ex-
pressing EBNA-3 or EBNA-5. EBNA-3 but not EBNA-5 in-
duced nuclear translocation of GFP-F538. C-terminally
truncated protein remained in cytoplasm. EBNA-3 re-dis-
tributed in the nucleus and formed nuclear precipitates to-
gether with GFP-F538. These two proteins showed a high
degree of co-localization (Figure
6A,6B,6C,6D,6E,6F,6G,6H,6I).
We raised rabbit polyclonal antibodies against the bacte-
rially produced GST-538 protein. Immunofluorescence
staining detected an almost exclusively cytoplasmic distri-
bution of F538 in the EBV negative BL cells DG75 (Figure
6J) and BL21 but gave a predominantly nuclear staining in
the EBV positive BL Raji (Figure 6K) or EBV transformed
lymphoblastoid cell lines Nadja, IARC171 and 940110
(Figure 6L).
Importantly the stable transfected clone of DG75 that
constitutively expressed EBNA-3 in more than 95% of the
cells showed nuclear accumulation of the F538 protein
(Figure 6N) whereas F538 remained cytoplasmic in DG75
cells stably transfected with EBNA-5 (Figure 6M). Optical
sections taken at high magnification using fluorescence
3D microscope showed that F538 preferentially accumu-
lated in the low DNA density areas of the nucleus of the
EBNA-3 expressing cells (Fig 6O).
We have built a 3D-structural model for the C-terminal
part of F538, starting from residue 309, using the SWISS-
MODEL program [14–16]. With very high probability E-
value (1e-51) it corresponded to the crystal structure of
Toxoplasma gondii uracil phosphoribosyltransferase (UP-
RT) [17] (Figure 7). UPRT (T. gondii) belongs to PRTase-
like superfamily, phosphoribosyltransferases (PRTases)
family with PRTase-like fold (SCOP classification). This
Figure 1
Northern blot for 2.4 kb F538 mRNA (top) shows an ubiqui-
tous expression in different human tissues. β -actin probe is
used as loading control on the same filter (bottom).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/23
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Figure 2
Sequence of F538 that is identical to the hypothetical protein FLJ20517. The sequence of the cDNA fragment isolated from the
yeast two hybrid screen is underlined (top) Sequence of the C terminal part of the alternatively spliced variant with the addi-
tional ten amino acids preceding the newly created stop-codon (bottom).
Figure 3
Exon structure and cloning strategy for the full length F538 and the C terminal truncated splice variant
I II III IV V VI VII IX X XI XII XIII XIV XV
5´ 3´
F538 protein
F538 Forward F538 Reverse
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5´ 3´
F538∆ ∆ ∆ ∆Cp r o t e i n
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I
X
∆  ∆  ∆  ∆ XI
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second half of F538 (309–548 aa) shows high sequence
similarity of three of the four conserved regions (I, II and
IV) where the binding sites for ribose (R) and uracil (U)
are located (Figure 8). Furthermore the predicted 3D
structure shows an almost identical folding even for the
region III despite the sequence difference. Structure and
composition of the active centre in UPRT (T. gondii) and
in F538 shows also very high similarity (Figure 9). The
flexible loop that is involved in the binding to another
monomeric unit is present as well. The 3D model of F538
suggests that the flexible loop is folded in a similar fash-
ion as in UPRT (T. gondii) where it is involved in the for-
mation of homo-dimer as well as homo-tetramer, that is
the active form of the enzyme (Figure 10).
The N-terminal part contains an ATP/GTP-binding site (P-
loop) suggesting that F538 also has a uridine kinase activ-
ity. High (37–42) aligning scores to the known uridine ki-
nases support this proposition (Figure 11). F538 most
probably consists of two domains with separate enzymat-
ic activity in a similar fashion as the C. elegans UK/UPRT
enzyme (Figure 12).
Discussion
In the cell nucleotides are made either by the de novo path-
way, or by the salvage pathway. The nucleosides can be sal-
vaged by nucleoside kinases or cleaved by nucleoside
phosphorylases to yield free bases and ribose-1-phos-
phate (desoxyribose-1-phosphate). The bases can be ei-
ther salvaged by phosphoribosyltransferases or
catabolized further.
Uridine kinase (UK) phosphorylates uridine to uridine
mono-phosphate (UMP) using ATP as a phosphate do-
nor:
Uridine+ATP →  UMP+ADP
Uracil phosphoribosyltransferase (UPRT) can salvage
uracil to UMP:
PRPP+uracil →  UMP+PPi,
where PRPP is 5-phosphoribosyl-1-pyrophosphate and
PPi is pyrophosphate. Uridine kinases, also called ATP
uridine 5' phosphotransferases, are rate-limiting enzymes
in the salvage pathway. Recently it was demonstrated that
Figure 4
GST-538, but not different control fusion proteins precipi-
tates EBNA-3 from CV-1 cell lysates infected with recom-
binant vaccinia virus as detected by Western blotting.
Figure 5
GFP-F538 localize to the cytoplasm of transfected CV1 cells.
Depending on the level of expression it shows homogeneous
(5–8 hours after transfection – top row), speckled (24 hours
after transfection – middle row) or massively granular distri-
bution (48 hours after transfection – bottom row). DNA
staining with Hoechst 33258 is blue.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/23
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Figure 6
Expression of EBNA-3 (B, E, H – red) from recombinant vaccinia virus in cells that were transfected with GFP-F538 (A, D, G –
green) leads to the accumulation of GFP-F538 in the nucleus in parallel with the redistribution of EBNA-3 from homogeneous
nucleoplasmic pattern to well circumscribed nuclear granules. In these granules EBNA-3 (H) shows high levels of co-localiza-
tion (I) with GFP-F538 (G). Expression of EBNA-5 (C – red) from recombinant vaccinia virus does not change the cytoplasmic
localization of GFP-F538 (C – green). Immunofluorescence staining of endogeneous F538 protein with rabbit polyclonal anti-
bodies shows cytoplasmic distribution in the EBV negative BL cells DG75 (J) but gives predominantly nuclear staining in EBV
positive BL cells Raji (K) or EBV transformed lymphoblastoid cell line 940110 (L). DG75 cells that express EBNA-5 show the
same cytoplasmic distribution as the parental cells (M) whereas EBNA-3 expressing DG75 cells demonstrate nuclear accumu-
lation of the F538 protein (N). High magnification image of the nucleus show that F538 preferentially accumulates in low DNA
density areas that corresponds to the euchromatin (O) DNA staining with Hoechst 33258 is blue.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/23
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uracil salvage might take place also in mammalian (rat)
cells, but the responsible enzyme was still unidentified
[18]. It was also shown that the activity of uridine kinases
is increased 5–13 fold in human colon tumors [19] ovar-
ian carcinomas, hepatocellular carcinomas [20] and dam-
aged tissues [21]. The level of expression was however very
low in normal tissues [22]. At present, two human uridine
kinases are known: human uridine kinase 1 (HUCK1 –
AAK49122) and human uridine kinase 2 (HUCK2 –
AAK14053).
The N-terminal half of F538 shows high sequence similar-
ity to both UCK1 and UCK2. UCK1 and UCK2 share 70%
of identity at the protein level. F538 shows 38% identity
to the UK/UPRT of Cryptosporidium parvum (accession
number AAG53652), 50% identity to the UPRT of Toxo-
plasma gondii (accession number Q26998) and 51%
identity to the UK/UPRT of C. elegans (accession number
CAA93459).
Three of four conservative domains and binding sites are
present in F538 and UK/UPRT as well as in UPRT.
On the basis of the high homology to UK and UK/UPRT
and the similar 3D structure of the C-terminal part of
F538 to the T. gondii UPRT, we propose that F538 is a
novel uridine kinas/uracil phosphoribosyltransferase
(UK/UPRT) – an enzyme with double catalytic activity.
The protein coded by F538∆ C lacks the UPRT domain but
may function as uridine kinase.
Uridine kinases and UPRTs play an important role in the
salvage pathway of RNA-synthesis. It was suggested [23]
that de novo synthesized UTP is preferentially used for the
production of UDP-sugars and phospholipids, while UTP,
made by the salvage pathway, is used for RNA-synthesis.
Uridine kinase activity is increased in the tumor cells. The
increase of the nuclear UTP pool may be an important fac-
tor for maintenance of high proliferation rate. We suggest
that the nuclear accumulation of this novel human UK/
Figure 7
Predicted 3D structure of F538 (aa 309–542) as space fill model in comparison to the crystal structure of T. gondii UPRT (2.5
Å resolution – Schumacher et al, 1998). The bound UMP is red.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/23
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Figure 8
Protein sequence alignment of F538 and UPRT of Toxoplasma gondii. The four conserved regions are underlined. R – ribose
binding residue, U – uracil binding residues.
Figure 9
The structure of T. gondii UPRT active center with coordinated UMP (white balls and sticks) as compared to the predicted
SWISSModel structure of F538. The UPRT conserved region III that shows the highest difference between the two proteins
still exhibits the same folding pattern (black line on the backbone)BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/23
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Figure 10
The structure of the predicted dimer derived from SWISSModel for F538. Reaction product – UMP is shown in red. N – and
C-termini are indicated.
Figure 11
Multiple alignments of the N terminus of F538, mouse uridine kinase (P52263), UK/UPRT of Cryptosporidium parvum
(AAG53652) and UK/UPRT of C. elegans (CAA93459). P-loop (ATP/GTP-binding site) is underlined.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/23
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UPRT may be part of the viral strategy to convert a resting
B cell to continuously proliferating lymphoblasts by se-
curing a salvage pathway enzyme at the site of the RNA
synthesis.
We have shown that F538 interacts specifically with
EBNA-3 in the yeast two-hybrid system and in GST pull
down assays. The predominantly cytoplasmic GFP-F538
translocates to the nucleus when EBNA-3 is expressed.
GFP-F538∆ C is not targeted to the nucleus by EBNA-3.
This together with the sequence position of the cDNA
fragment recovered from the yeast two hybrid screen indi-
cates that binding site of F538 to EBNA-3 is located be-
tween residue 368 and 473, where the conserved domains
of UPRT are located.
Conclusions
Our data suggest that EBNA-3 may bring an enzyme that
participate in the uridine salvage pathway to the euchro-
matic part of the nucleus. Through this, EBNA-3 may con-
tribute to the increase of UTP nuclear pool, that in turn is
needed for increased cell proliferation.
Methods
Plasmids
The polylinker region of the GAL-4 DNA-binding domain
containing pGBT9 vector (Clontech) was modified to
make it compatible with the GST-2TK expression vector
(designated as BD). For AD-F538 cloning we have used
pGAD424 vector from Clontech.
Construction of the plasmids Full436/GST-2TK, NEBNA-
1/BD, ∆ EBNA-4/BD, EBNA-5/BD, EBNA-5/GST-2TK, was
previously described [12].
N-terminus truncated mouse p53 in pGBT9 (pVA3) and
SV40 Large T-antigen in pGAD10 (pTD1, both from Clon-
tech) were used as positive interaction controls.
The GFP-F538 and AD-F538 were generated by inserting
the 1642 bp PCR-product into the respective vectors
(primers are described below) corresponding to amino ac-
ids 11 – 548 of the NP_060329.
Figure 12
Multiple alignments of the C terminus of F538, T. gondii phosphoribosyltransferase (Q26998), UK/UPRT of Cryptosporidium par-
vum (AAG53652) and UK/UPRT of C. elegans (CAA93459).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/23
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Yeast strains and cDNA library screening
The Saccharomyces cerevisiae HF7c strain was used for li-
brary screening and SFY526 for confirmation of the inter-
action upon retransformation. Human lymphocyte
MATCHMAKER cDNA library in pACT GAL-4 transcrip-
tional activation domain vector along with the yeast
strains were obtained from Clontech. Library screening
was done according the Clontech protocol. Interacting
clones were selected on SD plates lacking His, Leu and
Trp. The fastest growing clones were further tested for β -
galactosidase activity by ONPG test as described [24]. Spe-
cific activity of the given clones was calculated as percent-
age of β -galactosidase units of the positive control. The
samples were incubated with ONPG at 30°C for 2 hours.
Sequencing
Sequencing was done using capillary Apply BioSystem se-
quence machine (Perkin-Elmer).
Northern blotting
Northern blotting was carried out according to manufac-
turer protocol on ready m-RNA blot (Cat. #7760-1, Clon-
tech).
PCR
PCR was carried using Perkin-Elmer or Idahotech thermo-
cyclers.
Primers to amplify the F538 sequence:
5' primers: CGGGATCCGATCCTTCGCCCACGTCGCC
(for GFP), GGAATTCGATCCTTCGCCCACGTCGCC (for
pGAD424).
3' primer: GGAATTCTCACTGGGCAGCTAACCCGT (for
GFP), CGGGATCCTCACTGGGCAGCTAACCCGT (for
pGAD424).
Sequencing primers:
5' primer: CCACCCTCAAGAAGCTGAAG
3' primer:GGTAAGCTGGTTGGTCTGGAT.
Primers were obtained from GIBCO BRL.
Cells and cell culture
All cell lines were cultured at 37°C, in Iscove's medium
containing 10% fetal bovine serum. Periodic staining with
Hoechst 33258 was used to monitore the absence of myc-
oplasma. CV1 cells were infected at high multiplicity with
recombinant vaccinia virus encoding EBNA-3 or EBNA-5
as described [12]. CV1 was transfected with GFP-F538 or
GFP-F538∆ C construct using Lipofectamine Plus Reagent
(Life Technology) according to the manufacturer's proto-
col. Infection with recombinant vaccinia viruses was done
as described [25].
GST pull down assay
GST pull down assay was performed as described [12]. All
cell lysates contained 0,5 % of BSA as non-specific com-
petitor.
Immunofluorescence staining
Immunostaining and digital image capturing was carried
out as described [26–28] using the anti-EBNA-3A mono-
clonal antibody T2.78–19 (kind gift of M. Rowe) and anti-
EBNA-5 monoclonal antibody JF186. The polyclonal rab-
bit antibodies against GST-538 were produced by ASLA,
Ltd, Riga, Latvia.
Molecular modelling
3D modelling was run using SWISS-MODEL, an automat-
ed comparative protein modelling server [14–16]. The
software was obtained from ExPASy molecular biology
server  [http://www.expasy.ch/].
Multiple alignment
Multiple aligning was run using Clustalw program [29]
obtained from EMBL, European Bioinformatics Institute
[http://ww.ebi.ac.uk/clustalw/]. We used the default pa-
rameters with BLOSUM matrix (gap opening value 10,
gap extension value 0,05). Similar results were obtained
using another aligning program – MAXHOM [30].
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